PIA
HZNP

Piedmont Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Piedmont Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-101,825
Closed -$1.69M – 2838
2018
Q2 		$1.69M Buy
101,825
+56,655
+125% +$864K 0.08% 242
2018
Q1 		$641K Hold
45,170
– – 0.02% 362
2017
Q4 		$659K Buy
+45,170
New +$634K 0.01% 351

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Piedmont Investment Advisors's HZNP Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2018, closing a stake of 101,825 shares — an estimated $1.69M sold.

Piedmont Investment Advisors first reported a position in HZNP in Q4 2017 and held it in 3 quarters. The position peaked at $1.69M in Q2 2018. 221 funds tracked by Wall St. Rank hold HZNP as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 101,825 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2018, an estimated $1.69M.
  • Piedmont Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 3 quarters.
  • Piedmont Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.69M in Q2 2018.
  • 221 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.